Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors
BioNTech SE
BioNTech SE
OHSU Knight Cancer Institute
Seagen Inc.
Halozyme Therapeutics
Incyte Corporation
Incyte Corporation
Icahn School of Medicine at Mount Sinai